View ValuationFirebrick Pharma 将来の成長Future 基準チェック /06現在、 Firebrick Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長44.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listingお知らせ • Sep 29Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025.お知らせ • Aug 30Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Aug 26+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Jun 26Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,095,238 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Mar 05Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc.Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick.お知らせ • Oct 29Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024.お知らせ • Oct 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,885,454 Price\Range: AUD 0.055 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listingお知らせ • Sep 12+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,363,636 Price\Range: AUD 0.055Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).お知らせ • Sep 15Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common ColdFirebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment.Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).お知らせ • Jul 22Firebrick Update on Administrative Appeals Tribunal ProcessFirebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited.お知らせ • May 16Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy.Board Change • Mar 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Firebrick Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:FRE - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-2-2-2N/A9/30/20250-3-2-2N/A6/30/20251-3-2-2N/A3/31/20251-2-2-2N/A12/31/20241-2-2-2N/A9/30/20242-1-2-2N/A6/30/20243-1-2-2N/A3/31/20242-3-3-3N/A12/31/20232-5-5-5N/A9/30/20231-6-5-5N/A6/30/20230-7-6-6N/A3/31/20231-6-5-5N/A12/31/20221-5-5-5N/A9/30/20221-5-5-5N/A6/30/20221-4-4-4N/A3/31/20221-3-4-4N/A12/31/20210-3-3-3N/A9/30/20210-3-2-2N/A6/30/20210-2-2-2N/A6/30/20201-1-1-1N/A6/30/20190-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: FREの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: FREの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: FREの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: FREの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: FREの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: FREの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 11:20終値2026/07/03 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Firebrick Pharma Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 29Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025.
お知らせ • Aug 30Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Aug 26+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Jun 26Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,095,238 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Mar 05Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc.Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick.
お知らせ • Oct 29Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024.
お知らせ • Oct 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,885,454 Price\Range: AUD 0.055 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 12+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,363,636 Price\Range: AUD 0.055
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).
お知らせ • Sep 15Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common ColdFirebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment.
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).
お知らせ • Jul 22Firebrick Update on Administrative Appeals Tribunal ProcessFirebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited.
お知らせ • May 16Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy.
Board Change • Mar 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.